T. Rowe Price Associates
CORT icon

T. Rowe Price Associates’s Corcept Therapeutics CORT Stock Holding History

T. Rowe Price Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Buy
165,235
+78,645
+91% +$4.75M ﹤0.01% 1239
2026
Q1 		$3.49M Sell
86,590
-297,656
-77% -$11.1M ﹤0.01% 1584
2025
Q4 		$13.4M Buy
384,246
+1,186
+0.3% +$93.2K ﹤0.01% 1172
2025
Q3 		$31.8M Buy
383,060
+235,968
+160% +$17.1M ﹤0.01% 933
2025
Q2 		$10.8M Buy
147,092
+82,200
+127% +$5.96M ﹤0.01% 1096
2025
Q1 		$7.41M Buy
64,892
+10,139
+19% +$617K ﹤0.01% 1167
2024
Q4 		$2.76M Buy
54,753
+1,825
+3% +$95.6K ﹤0.01% 1491
2024
Q3 		$2.45M Buy
52,928
+1,793
+4% +$63.7K ﹤0.01% 1546
2024
Q2 		$1.66M Buy
51,135
+2,709
+6% +$74.2K ﹤0.01% 1649
2024
Q1 		$1.22M Sell
48,426
-3,109
-6% -$73.5K ﹤0.01% 1818
2023
Q4 		$1.67M Buy
51,535
+2,850
+6% +$78.3K ﹤0.01% 1626
2023
Q3 		$1.33M Buy
48,685
+2,042
+4% +$59.1K ﹤0.01% 1662
2023
Q2 		$1.04M Buy
46,643
+832
+2% +$19.1K ﹤0.01% 1789
2023
Q1 		$993K Buy
45,811
+2,201
+5% +$48.3K ﹤0.01% 1792
2022
Q4 		$886K Buy
43,610
+2,082
+5% +$52.2K ﹤0.01% 1840
2022
Q3 		$1.06M Buy
41,528
+5,731
+16% +$153K ﹤0.01% 1719
2022
Q2 		$851K Buy
35,797
+7,230
+25% +$158K ﹤0.01% 1975
2022
Q1 		$643K Buy
28,567
+4,030
+16% +$85.7K ﹤0.01% 2229
2021
Q4 		$486K Sell
24,537
-18,226
-43% -$370K ﹤0.01% 2395
2021
Q3 		$842K Buy
42,763
+200
+0.5% +$4.19K ﹤0.01% 2132
2021
Q2 		$936K Buy
42,563
+1,561
+4% +$34.7K ﹤0.01% 2098
2021
Q1 		$975K Sell
41,002
-135
-0.3% -$3.6K ﹤0.01% 2064
2020
Q4 		$1.08M Buy
+41,137
New +$867K ﹤0.01% 1905
2017
Q1 		– Sell
-88,815
Closed -$645K – 2574
2016
Q4 		$645K Buy
+88,815
New +$696K ﹤0.01% 1949
2016
Q2 		– Sell
-100,454
Closed -$470K – 2518
2016
Q1 		$470K Hold
100,454
– – ﹤0.01% 1998
2015
Q4 		$500K Sell
100,454
-286,181
-74% -$1.29M ﹤0.01% 1959
2015
Q3 		$1.45M Buy
+386,635
New +$1.96M ﹤0.01% 1607

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's CORT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Corcept Therapeutics (CORT) stake by 91% in Q2 2026, buying an estimated $4.75M and bringing the position to 165,235 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

T. Rowe Price Associates first reported a position in CORT in Q3 2015 and has held it in 27 quarters since. The position peaked at $31.8M in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • T. Rowe Price Associates held 165,235 shares of Corcept Therapeutics worth $14.4M as of Q2 2026.
  • T. Rowe Price Associates bought 78,645 Corcept Therapeutics shares in Q2 2026, an estimated $4.75M.
  • Corcept Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1239 holding.
  • T. Rowe Price Associates first reported a position in Corcept Therapeutics in Q3 2015 and has held it in 27 quarters since.
  • T. Rowe Price Associates's Corcept Therapeutics position peaked at $31.8M in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.